QuidelOrtho Corporation has announced its intention to acquire full ownership of LEX Diagnostics following the anticipated 510(k) clearance by the U.S. FDA. The transaction, valued at approximately $100 million at closing, signifies a strategic shift in QuidelOrtho's molecular diagnostics strategy. As part of this realignment, QuidelOrtho plans to discontinue the development of its Savanna® platform. This move aims to strengthen the company's presence in the rapidly growing point-of-care molecular diagnostics segment. The announcement was made by Brian J. Blaser, President and CEO of QuidelOrtho, who highlighted the performance advantages and growth opportunities offered by LEX Diagnostics.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。